Leap Therapeutics reports Q3 2022 net loss of $15.1M, up from $11.1M YoY

CYPHERPUNK TECHNOLOGIES INC.

2022-Q3 EPS reported -$0.38

Net loss $15.1M in Q3 2022 vs $11.1M in Q3 2021; R&D expenses $12.1M.
Cash and equivalents $78.3M at Sept 30, 2022; plus $1.3M R&D incentive receivable.
Enrolled first patient in Part C of DisTinGuish study (GEA) and DeFianCe study (CRC).
Presented updated DKN-01 clinical data at ESMO and SITC meetings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2022 results: net income $15.1 million.

Period: the third quarter ended September 30, 2022
Net income: $15.1 million
Result: reported results

Exact text from the filing

Net Loss was $15.1 million for the third quarter 2022, compared to $11.1 million for the three months ended September 30, 2021.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-117681

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.